667 related articles for article (PubMed ID: 34463174)
21. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
22. Synergistically Improved Anti-tumor Efficacy by Co-delivery Doxorubicin and Curcumin Polymeric Micelles.
Wang J; Ma W; Tu P
Macromol Biosci; 2015 Sep; 15(9):1252-61. PubMed ID: 25981672
[TBL] [Abstract][Full Text] [Related]
23. Bypassing multidrug resistant ovarian cancer using ultrasound responsive doxorubicin/curcumin co-deliver alginate nanodroplets.
Baghbani F; Moztarzadeh F
Colloids Surf B Biointerfaces; 2017 May; 153():132-140. PubMed ID: 28235723
[TBL] [Abstract][Full Text] [Related]
24. A complex micellar system co-delivering curcumin with doxorubicin against cardiotoxicity and tumor growth.
Zhang D; Xu Q; Wang N; Yang Y; Liu J; Yu G; Yang X; Xu H; Wang H
Int J Nanomedicine; 2018; 13():4549-4561. PubMed ID: 30127606
[TBL] [Abstract][Full Text] [Related]
25. Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier.
Lu J; Zhao W; Huang Y; Liu H; Marquez R; Gibbs RB; Li J; Venkataramanan R; Xu L; Li S; Li S
Mol Pharm; 2014 Nov; 11(11):4164-78. PubMed ID: 25265550
[TBL] [Abstract][Full Text] [Related]
26. Tuftsin-Bearing Liposomes Co-Encapsulated with Doxorubicin and Curcumin Efficiently Inhibit EAC Tumor Growth in Mice.
Murugesan K; Srinivasan P; Mahadeva R; Gupta CM; Haq W
Int J Nanomedicine; 2020; 15():10547-10559. PubMed ID: 33414637
[TBL] [Abstract][Full Text] [Related]
27. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery.
Zhang C; Zhao L; Dong Y; Zhang X; Lin J; Chen Z
Eur J Pharm Biopharm; 2010 Sep; 76(1):10-6. PubMed ID: 20472060
[TBL] [Abstract][Full Text] [Related]
28. Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer.
Zhao X; Chen Q; Liu W; Li Y; Tang H; Liu X; Yang X
Int J Nanomedicine; 2015; 10():257-70. PubMed ID: 25565818
[TBL] [Abstract][Full Text] [Related]
29. Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer.
Cheng X; Li D; Sun M; He L; Zheng Y; Wang X; Tang R
Colloids Surf B Biointerfaces; 2019 Sep; 181():185-197. PubMed ID: 31132609
[TBL] [Abstract][Full Text] [Related]
30. Folate-receptor mediated pH/reduction-responsive biomimetic nanoparticles for dually activated multi-stage anticancer drug delivery.
Wang D; Chen W; Li H; Huang G; Zhou Y; Wang Y; Wan W; You B; Liu Y; Zhang X
Int J Pharm; 2020 Jul; 585():119456. PubMed ID: 32492507
[TBL] [Abstract][Full Text] [Related]
31. Micelles of d-α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance.
Hao T; Chen D; Liu K; Qi Y; Tian Y; Sun P; Liu Y; Li Z
ACS Appl Mater Interfaces; 2015 Aug; 7(32):18064-75. PubMed ID: 26214761
[TBL] [Abstract][Full Text] [Related]
32. Tumor Targeted Curcumin Delivery by Folate-Modified MPEG-PCL Self-Assembly Micelles for Colorectal Cancer Therapy.
Hu Y; He Y; Ji J; Zheng S; Cheng Y
Int J Nanomedicine; 2020; 15():1239-1252. PubMed ID: 32110020
[TBL] [Abstract][Full Text] [Related]
33. Delivery of folic acid-modified liposomal curcumin for targeted cervical carcinoma therapy.
Wang WY; Cao YX; Zhou X; Wei B
Drug Des Devel Ther; 2019; 13():2205-2213. PubMed ID: 31308632
[No Abstract] [Full Text] [Related]
34. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
[TBL] [Abstract][Full Text] [Related]
35. Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance.
Wang H; Yin H; Yan F; Sun M; Du L; Peng W; Li Q; Feng Y; Zhou Y
Oncotarget; 2015 Feb; 6(5):2827-42. PubMed ID: 25605018
[TBL] [Abstract][Full Text] [Related]
36. Curcumin-Loaded Hybrid Nanoparticles: Microchannel-Based Preparation and Antitumor Activity in a Mouse Model.
Hong W; Gao Y; Lou B; Ying S; Wu W; Ji X; Yu N; Jiao Y; Wang H; Zhou X; Li A; Guo F; Yang G
Int J Nanomedicine; 2021; 16():4147-4159. PubMed ID: 34168445
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of a novel biocompatible magnetic nanomedicine based on beta-cyclodextrin, loaded doxorubicin-curcumin for overcoming chemoresistance in breast cancer.
Rastegar R; Akbari Javar H; Khoobi M; Dehghan Kelishadi P; Hossein Yousefi G; Doosti M; Hossien Ghahremani M; Shariftabrizi A; Imanparast F; Gholibeglu E; Gholami M
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):207-216. PubMed ID: 29688063
[TBL] [Abstract][Full Text] [Related]
38. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.
Misra R; Sahoo SK
Mol Pharm; 2011 Jun; 8(3):852-66. PubMed ID: 21480667
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
40. Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation.
Alibolandi M; Abnous K; Sadeghi F; Hosseinkhani H; Ramezani M; Hadizadeh F
Int J Pharm; 2016 Mar; 500(1-2):162-78. PubMed ID: 26802496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
